Philips introduced its Rembra CT system at the European Congress of Radiology in Vienna, unveiling the largest‑bore frontline scanner yet. The 85‑centimeter bore, the widest in its class, is designed for treatment preparation and planning rather than routine diagnostics, giving clinicians a broader field of view for complex cases.
The system delivers an unprecedented reconstruction speed of up to 106 images per second and can support up to 270 examinations in a 16‑hour day, a throughput benchmark based on 203 patient scans completed in 12 hours during testing. AI‑powered smart workflows automate routine steps, further reducing diagnostic turnaround times and enhancing clinical confidence.
Philips positions Rembra as a key component of its strategy to dominate the high‑acuity imaging market, competing with Siemens Healthineers and GE HealthCare. By combining speed, a large field of view, and AI integration, the scanner addresses the growing demand for rapid, high‑volume imaging in emergency and trauma settings.
The Rembra CT is CE‑marked and 510(k) pending, meaning it is not yet available in the United States. Philips also introduced the Verida spectral CT at the same congress, underscoring a broader push toward AI‑driven imaging solutions.
Dan Xu, Philips’ Business Leader for Computed Tomography, said, “Rembra is built for the realities that clinicians face every day. By combining our most advanced detector technology with AI‑powered workflows and industry‑leading speed, Rembra represents a significant step forward for high‑acuity imaging, delivering speed, access and diagnostic confidence when it matters most.”
The launch signals Philips’ commitment to improving workflow efficiency in high‑volume clinical environments and may strengthen its competitive position against rivals that are also investing heavily in speed and AI.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.